Here’s why this pot stock gained a stunning 40% this morning
Nick Sundich, October 3, 2023
As of 10.30am this morning, the biggest gaining ASX stock with news was pot stock ECS Botanics (ASX:ECS), all thanks to a $24m offtake deal.
SIGN UP FOR THE STOCKS DOWN UNDER NEWSLETTER NOW!
Is this pot stock coming alive again?
The fortune of pot stocks rise and fall with changes in global regulations that investors anticipate will lead to the market being unlocked. They rise when changes are announced but then fall when investors realise that either it isn’t unlocked or even when it is, the company they thought would be in for a windfall is just a little fish in a big pond.
So it has been for ECS Botanics, a company that claims to be Australia’s largest B2B medicinal cannabis cultivator & manufacturer. But, today’s news was nothing to be snuffed at.
ECS told its shareholders it secured a five year offtake deal with MediCann Health. This binding deal will see ECS supply MediCann with $24m of medicinal cannabis dried flower, starting in January 2024. This builds on an existing deals it has with MediCann that is worth $11.9m.
Is this pot stock for real?
ECS is certainly better poised than a company that has a non-binding MoU. But investors should remember that the medicinal cannabis industry is still relatively nascent and highly regulated, both in Australia and globally.
There is potential for long-term investors to make money if they back the right company, are prepared to deal with short-term volatility and wait for a few years. But not for short-term day traders trying to profit off the next regulatory change.
What are the Best biotech stocks to invest in right now?
Check our buy/sell stock tips
Blog Categories
Get Our Top 5 ASX Stocks for FY25
Recent Posts
Analysts aren’t optimistic about iron ore prices in 2025, will they be right and what will it mean for iron ore stocks?
In which direction will iron ore prices in 2025 go? Chinese trade data would suggest upwards, and indeed prices jumped…
Paradigm Biopharmaceuticals’ flagship drug Zilosul will be in Phase 3 in 2025
Paradigm Biopharmaceuticals (ASX:PAR) has been listed for nearly a decade with the goal of bringing its flagship drug pentosan polysulfate…
Findi (ASX:FND): Its quadrupled in 12 months off the back of financial services in India
Until Findi (ASX:FND) came along, there were practically no ASX companies making money from India (or at least not many…